Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of acute coronary syndrome as well as the prognosis. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging. The global cardiac biomarkers market is expected to increase by USD 7 billion, at a compound annual growth rate (CAGR) of 9.3% from 2022 to 2028, according to the latest edition of the Global Cardiac Biomarkers Market Report.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global cardiac biomarkers market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the cardiac biomarkers industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type, location of testing, application, and region. The global market for cardiac biomarkers can be segmented by type: albumin, creatine kinase-MB (CK-MB), low-density lipoproteins (LDL) and high-density lipoproteins (HDL), myoglobin, natriuretic peptides – B-type natriuretic peptide (BNP) & N-terminal pro b-type natriuretic peptide (NT-proBNP), troponins, others. Cardiac biomarkers market is further segmented by location of testing: laboratory testing, point of care testing. Based on application, the cardiac biomarkers market is segmented into: acute coronary syndrome, atherosclerosis, congestive heart failure, myocardial infarction, others. On the basis of region, the cardiac biomarkers market also can be divided into: North America, Asia Pacific, Europe, Rest of the World (ROW).

By type:
– albumin
– creatine kinase-MB (CK-MB)
– low-density lipoproteins (LDL) and high-density lipoproteins (HDL)
– myoglobin
– natriuretic peptides – B-type natriuretic peptide (BNP) & N-terminal pro b-type natriuretic peptide (NT-proBNP)
– troponins
– others

By location of testing:
– laboratory testing
– point of care testing

By application:
– acute coronary syndrome
– atherosclerosis
– congestive heart failure
– myocardial infarction
– others

By region:
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)

The report also provides a detailed analysis of several leading cardiac biomarkers market vendors that include Abbott Laboratories, ACS Biomarker B.V., bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis AG, QuidelOrtho Corporation, Randox Laboratories Ltd., Siemens AG, Thermo Fisher Scientific Inc., Tosoh Bioscience, Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global cardiac biomarkers market.
– To classify and forecast the global cardiac biomarkers market based on type, location of testing, application, region.
– To identify drivers and challenges for the global cardiac biomarkers market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cardiac biomarkers market.
– To identify and analyze the profile of leading players operating in the global cardiac biomarkers market.

Why Choose This Report
– Gain a reliable outlook of the global cardiac biomarkers market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.